These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2006810)

  • 81. [Geriatric pharmacology: start with half of the smallest dose and increase slowly thereafter].
    Latour J
    Union Med Can; 1992; 121(1):4-6, 8, 10. PubMed ID: 1539401
    [No Abstract]   [Full Text] [Related]  

  • 82. [Precautions in use of drugs for elderly patients].
    Mikami H
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():42-7. PubMed ID: 18074515
    [No Abstract]   [Full Text] [Related]  

  • 83. Identification of circadian clock modulators from existing drugs.
    Tamai TK; Nakane Y; Ota W; Kobayashi A; Ishiguro M; Kadofusa N; Ikegami K; Yagita K; Shigeyoshi Y; Sudo M; Nishiwaki-Ohkawa T; Sato A; Yoshimura T
    EMBO Mol Med; 2018 May; 10(5):. PubMed ID: 29666146
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Medicine partnerships.
    Cramer J
    Heart; 2003 May; 89 Suppl 2(Suppl 2):ii19-21; discussion ii35-7. PubMed ID: 12695430
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Community nursing: always look at the patient's tablets...you might learn a lot.
    Morris D
    Nurs Mirror; 1978 Dec; 147(25):34-5. PubMed ID: 252059
    [No Abstract]   [Full Text] [Related]  

  • 86. European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement.
    van Boven JF; Tsiligianni I; Potočnjak I; Mihajlović J; Dima AL; Nabergoj Makovec U; Ágh T; Kardas P; Ghiciuc CM; Petrova G; Bitterman N; Kamberi F; Culig J; Wettermark B
    Front Pharmacol; 2021; 12():748702. PubMed ID: 34707502
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Design and conduct of confirmatory chronic pain clinical trials.
    Katz N
    Pain Rep; 2021; 6(1):e845. PubMed ID: 33511323
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study.
    Mallayasamy S; Chaturvedula A; Blaschke T; Fossler MJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Dec; 7(12):818-828. PubMed ID: 30291680
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity.
    Bauer R; Glenn T; Alda M; Sagduyu K; Marsh W; Grof P; Munoz R; Murray G; Ritter P; Lewitzka U; Severus E; Whybrow PC; Bauer M
    Int J Bipolar Disord; 2013; 1():26. PubMed ID: 25505689
    [TBL] [Abstract][Full Text] [Related]  

  • 90. An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy.
    Aylward BS; Rausch JR; Modi AC
    J Pediatr Psychol; 2015; 40(1):66-74. PubMed ID: 24648257
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Compliance spectrum as a drug fingerprint of drug intake and drug disposition.
    Barrière O; Li J; Nekka F
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):41-52. PubMed ID: 23250805
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
    Savic RM; Barrail-Tran A; Duval X; Nembot G; Panhard X; Descamps D; Verstuyft C; Vrijens B; Taburet AM; Goujard C; Mentré F;
    Clin Pharmacol Ther; 2012 Nov; 92(5):575-83. PubMed ID: 23033116
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The meaning of adherence when behavioral risk patterns vary: obscured use- and method-effectiveness in HIV-prevention trials.
    de Bruin M; Viechtbauer W
    PLoS One; 2012; 7(8):e44029. PubMed ID: 22970107
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.
    Eichler HG; Abadie E; Breckenridge A; Flamion B; Gustafsson LL; Leufkens H; Rowland M; Schneider CK; Bloechl-Daum B
    Nat Rev Drug Discov; 2011 Jul; 10(7):495-506. PubMed ID: 21720406
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Refilling and switching of antiepileptic drugs and seizure-related events.
    Gagne JJ; Avorn J; Shrank WH; Schneeweiss S
    Clin Pharmacol Ther; 2010 Sep; 88(3):347-53. PubMed ID: 20631693
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.
    Bi GD; Li J; Nekka F
    Theor Biol Med Model; 2009 Jun; 6():10. PubMed ID: 19558679
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A single-dose combination therapy that both prevents and treats anthrax infection.
    Klinman DM; Tross D
    Vaccine; 2009 Mar; 27(12):1811-5. PubMed ID: 19402202
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response.
    Urquhart J
    Br J Clin Pharmacol; 2002 Aug; 54(2):212-20. PubMed ID: 12207644
    [No Abstract]   [Full Text] [Related]  

  • 99. Accounting for noncompliance in pharmacoeconomic evaluations.
    Hughes DA; Bagust A; Haycox A; Walley T
    Pharmacoeconomics; 2001; 19(12):1185-97. PubMed ID: 11772154
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Role of patient compliance in clinical pharmacokinetics. A review of recent research.
    Urquhart J
    Clin Pharmacokinet; 1994 Sep; 27(3):202-15. PubMed ID: 7988102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.